Stay updated on Geptanolimab+Fruquintinib in Metastatic Colorectal Cancer Clinical Trial
Sign up to get notified when there's something new on the Geptanolimab+Fruquintinib in Metastatic Colorectal Cancer Clinical Trial page.

Latest updates to the Geptanolimab+Fruquintinib in Metastatic Colorectal Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page now displays the clinical trial record for geptanolimab combined with fruquintinib, including study design, eligibility criteria, outcomes, and contact details.SummaryDifference52%

- Check14 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA site-wide NIH announcement banner appears above the page, linking to transition updates and describing a terminology change from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check28 days agoChange DetectedThe footer’s site revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check35 days agoChange DetectedThe site revision identifier in the footer changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study details, indicating access restrictions to the ClinicalTrials.gov entry.SummaryDifference19%

Stay in the know with updates to Geptanolimab+Fruquintinib in Metastatic Colorectal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Geptanolimab+Fruquintinib in Metastatic Colorectal Cancer Clinical Trial page.